Posted 19th November 2024
Posted 2 months ago
By NHP Office
New NHP Chair Announced – Dr Kate Gardner
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Recent updates
The haemoglobinopathy community is constantly evolving. Here we share some highlights of the NHP, its network members and its stakeholders regarding advances in their improvement, harmonisation and equity goals and efforts.
Features
Posted 21st October 2024
Posted 3 months ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Posted 10th October 2024
Posted 3 months ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 25th September 2024
Posted 4 months ago
By NHP Office
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
Publications
Posted 21st November 2024
Posted 2 months ago
By NHP Office
NHP 2023/2024 Annual Report
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Posted 19th November 2024
Posted 2 months ago
By NHP Office
New NHP Chair Announced – Dr Kate Gardner
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Posted 21st October 2024
Posted 3 months ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Posted 10th October 2024
Posted 3 months ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
News & Updates
Posted 21st November 2024
Posted 2 months ago
By NHP Office
NHP 2023/2024 Annual Report
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Posted 19th November 2024
Posted 2 months ago
By NHP Office
New NHP Chair Announced – Dr Kate Gardner
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Posted 10th October 2024
Posted 3 months ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 25th September 2024
Posted 4 months ago
By NHP Office
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
